France· FR:61640118
ISTURISA 10 mg, comprimé pelliculé
A osilodrostat product containing phosphate d'osilodrostat, registered in France by RECORDATI RARE DISEASES, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Osilodrostat is registered in 14 of 19 countries.
Countries holding a registration under ATC H02CA02 (osilodrostat), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Osilodrostat · ATC H02CA02
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of osilodrostat costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.21 in France to $389.38 in Italy — a ×1832 gap.
- France: $0.21 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Osilodrostat · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- IT Italy$389.38
- CH Switzerland$250.17
- FR France$0.21
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PHOSPHATE D'OSILODROSTAT
- Manufacturer
- RECORDATI RARE DISEASES
- Country
- France (FR)
- ATC code
- H02CA02
- ATC class
- Osilodrostat
- Defined daily dose
- 10 mg, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930198360plaquette(s) aluminium de 60 comprimé(s) (6x10)EUR 5.87
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
488 interactions on record for osilodrostat.
Graded by severity as the source publishes them — 117 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Osilodrostat · interactions on record
488 records
- 117 severe
- 361 moderate
- 10 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Osilodrostat in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumIsturisa 10 mgRecordati Rare Diseases
- SwitzerlandIsturisa
- CzechiaISTURISARecordati Rare Diseases, Puteaux
- SpainISTURISA 10 mg COMPRIMIDOS RECUBIERTOS CON PELICULARecordati Rare Diseases
- FinlandIsturisaRecordati Rare Diseases
- IrelandIsturisa 10 mg film-coated tabletsRecordati Rare Diseases
- IcelandIsturisaRecordati Rare Diseases*
- NetherlandsIsturisa 10 mg filmomhulde tablettenRecordati Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Isturisa
- Liechtenstein · Isturisa
- Norway · Isturisa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fa72b035-e2b7-45f4-86ca-a530411c6179 GET /v1/drugs/fa72b035-e2b7-45f4-86ca-a530411c6179?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61640118",
"date_amm": "2020-01-09",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/19/1407",
"substance": "PHOSPHATE D'OSILODROSTAT",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about osilodrostat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.